Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation

被引：2

作者：

Granda, P. ^{[1
]}

Villamanan, E. ^{[2
,3
,4
,9
]}

Heinz, S. ^{[1
]}

Laorden, D. ^{[3
,5
]}

Romero, D. ^{[3
,6
]}

Anon, J. m ^{[3
,7
,8
]}

Carpio, C. ^{[3
,4
,5
]}

Sobrino, C. ^{[2
,3
]}

Collada, V ^{[2
,3
]}

Dominguez-Ortega, J. ^{[3
,8
]}

Herrero, A. ^{[2
,3
]}

Quirce, S. ^{[8
]}

alvarez-Sala, R. ^{[3
,4
,5
]}

机构：

[1] Hosp Cent Def Gomez Ulla, Pharm Dept, Madrid, Spain

[2] Hosp Univ La Paz, Pharm Dept, Madrid, Spain

[3] IdiPAZ, Madrid, Spain

[4] Univ Autonoma Madrid, Dept Med, Madrid, Spain

[5] Hosp Univ La Paz, Pulmonol Dept, Madrid 28046, Spain

[6] Hosp Univ La Paz, Intens Care Unit, Inst Salud Carlos III, Madrid, Spain

[7] Inst Salud Carlos III, CIBERes, Madrid, Spain

[8] Hosp Univ La Paz, Dept Allergy, IdiPAZ, Madrid, Spain

[9] Hosp Univ La Paz, La Paz Univ Hosp, Pharm Dept, Paseo Castellana 263, Madrid 28046, Spain

来源：

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY | 2024年 / 34卷 / 01期

关键词：

Severe asthma; Critical care; Reslizumab;

D O I：

10.18176/jiaci.0920

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：60 / 61

页数：2

共 9 条

[1] Will the asthma revolution fostered by biologics also benefit adult ICU patients? [J].

Bourdin, Arnaud ;

Charriot, Jeremy ;

Boissin, Clement ;

Ahmed, Engi ;

Suehs, Carey ;

De Sevin, Arthur ;

Volpato, Mathilde ;

Pahus, Laurie ;

Gras, Delphine ;

Vachier, Isabelle ;

Halimi, Laurence ;

Hamerlijnck, Dominic ;

Chanez, Pascal .

ALLERGY, 2021, 76 (08) :2395-2406

[2] Response to Monoclonal Antibodies in Asthma: Definitions, Potential Reasons for Failure, and Therapeutic Options for Suboptimal Response [J].

de Llano, Perez L. ;

Cisneros, C. ;

Dominguez-Ortega, J. ;

Martinez-Moragon, E. ;

Olaguibel, J. M. ;

Plaza, V ;

Quirce, S. ;

Davila, I .

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2023, 33 (01) :1-13

[3]

European Medicines Agency, Nucala (mepolizumab) public assessment report

[4]

European Medicines Agency, Fasenra (benralizumab) public assessment report

[5] Anti-IL-5 therapies for asthma [J].

Farne, Hugo A. ;

Wilson, Amanda ;

Milan, Stephen J. ;

Banchoff, Emma ;

Yang, Freda ;

Powell, Colin V. E. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (07)

[6] Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab [J].

Mukherjee, Manali ;

Paramo, Fernando Aleman ;

Kjarsgaard, Melanie ;

Salter, Brittany ;

Nair, Gayatri ;

LaVigne, Nicola ;

Radford, Katherine ;

Sehmi, Roma ;

Nair, Parameswaran .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (01) :38-46

[7] Compassionate Use of a Single Dose of Benralizumab in a Near-Fatal Asthma Exacerbation [J].

Perez de Llano, L. ;

Blanco Cid, N. ;

Ortiz Piquer, M. ;

Dacal Rivas, D. .

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2021, 31 (03) :268-+

[8] Reslizumab in an invasively ventilated patient with acute respiratory failure [J].

Renner, Andreas ;

Marth, Katharina ;

Schaeffl-Doweik, Lilian ;

Pohl, Wolfgang .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (08) :2922-2923

[9] Systemic inflammatory response syndrome (SIRS) after extracorporeal membrane oxygenation (ECMO): Incidence, risks and survivals [J].

Thangappan, Karthik ;

Cavarocchi, Nicholas C. ;

Baram, Michael ;

Thoma, Brandi ;

Hirose, Hitoshi .

HEART & LUNG, 2016, 45 (05) :449-453

← 1 →